Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer Protein
Catalog No: MAGEA10-HP002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and GLYDGMEHL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &GLYDGMEHL).
Product Details
- Molecular Aliases
- MAGE-A10
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer is greater than 95% as determined by SEC-HPLC.
Background
MAGE-A10 is a subtype of the Melanoma-associated antigen A (MAGE-A), a class of tumor antigens that are extensively expressed in various histological types of tumors and represents an attractive target for tumor immunotherapy. High-level expression of MAGE-A10 improved the anti-tumor immune cytotoxicity of MAGE-A10-specific CTLs in lung cancer cell lines and primary lung cancer cells.
References
- Li Z, Guo P, Guo P, Dong K, Liu F, Wu Y, Li J, Shan B, Sang M. 5-aza-2'-deoxycytidine (DAC) treatment induces the MAGE-A10 expression and improves the cytotoxicity of MAGE-A10-specific CTLs in lung cancer cells. Transl Cancer Res. 2020 Feb;9(2):1235-1245. doi: 10.21037/tcr.2020.01.10. PMID: 35117468; PMCID: PMC8798493.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.